ClinicalTrials.gg
RecruitingNCT07224711IMPALA ERASUpdated Nov 2, 2026

The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery

A Phase 4 interventional study of Lidocaine HCl 0.8% in D5W and Dextrose 5% in water in Pain, Post Operative Analgesia and Opioid Consumption, Postoperative, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Vanderbilt University Medical Center · Phase 4, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,290
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.

Planned enrollment
Largest of 203
2,290 · median 66
Started
2026
with 7 others
Phase 4
63 of 204
6 open now
Primary completion
2028-10
later than 16 of 18 live
Registered
193rd of 204
by date

Among the 204 studies testing lidocaine in Pain, this one has the largest planned enrollment of the 203 interventional ones that give a count, is one of 8 that started in 2026, is one of 63 in phase 4, reaches primary completion later than 16 of the 18 other live ones, and was the 193rd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies testing lidocaine in Pain, or all of them as a file.
02

Study summary

The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aims to answer are:

The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS).

The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).

03

Conditions studied

  • Pain
  • Post Operative Analgesia
  • Opioid Consumption, Postoperative

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18
  • (ASA) class I-IV
  • Presenting for major elective, non-cardiac surgery on the colorectal, emergency general surgery, urology, ventral hernia, surgical oncology, or spine services on a weekday
  • First surgery in the study period (if a patient has multiple surgeries, only the first will be included)

Exclusion criteria

Exclusion criteria:

  • >IV
  • Emergent procedures
  • Allergy or any to lidocaine infusion
  • Patient refusal
  • Unable to receive or refusal to receive a regional nerve block
  • Patients who receive an epidural due to standard of care
  • Direct transfer from operating room to ICU with endotracheal tube in place
  • Treating team determines patient ineligible prior to study drug administration
  • Same day surgery
  • Pregnancy (all female patient of child-bearing age will undergo a pregnancy test the day of surgery)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,290 participants (estimated)

Study arms

  • Active comparator
    LIdocaine

    Participants randomized to receive 1.5 mg /kg bolus of 0.8% lidocaine Hydrochoride (HCL) in dextrose 5% in water (D5W) via IV with induction, prior to infusion started. The IV bolus will be followed by continuous IV infusion of 2 mg/minute of 0.8% lidocaine HCl in D5W intraoperatively with weight-based gradated dosing postoperatively (1-2 mg/minute)

    Drug: Lidocaine HCl 0.8% in D5W

  • Placebo comparator
    Placebo

    Participants randomized to receive dextrose 5% in water (D5W) via IV with induction, prior to infusion started. The IV bolus will be equivalent in volume to the lidocaine arm. The bolus will be followed by continuous IV infusion intraoperatively and then up to 48 hours. The continuous IV infusion will be equivalent in volume and rate to the lidocaine arm.

    Drug: Dextrose 5% in water

Interventions

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1.5 mg /kg bolus of 0.8%lidocaine HCl in D5W via IV with induction, prior to infusion started. The IV bolus will be followed by continuous IV infusion of 2 mg/minute of 0.8% lidocaine HCl in D5W intraoperatively with weight-based gradated dosing postoperatively (1-2 mg/minute)

  • DrugDextrose 5% in water

    Dextrose 5% in water (D5W) via IV with induction, prior to infusion started. The IV bolus will be equivalent in volume to the lidocaine arm. The bolus will be followed by continuous IV infusion intraoperatively and then up to 48 hours. The continuous IV infusion will be equivalent in volume and rate to the lidocaine arm.

06

What researchers measure

Primary outcomes

  1. Case Mix Index-Adjusted Resource Length of Stay (CARLOS)

    The difference of CARLOS between the placebo and experimental groups in days. The Case Mix Index-Adjusted Resource Length of Stay is a hospital quality metric that standardizes average length of stay (LOS) to account for the complexity and severity of a hospital's patient population, represented by its Case Mix Index (CMI). A higher CMI indicates a more resource-intensive patient group, while a lower CMI reflects a simpler, less costly case mix.

    Time frame: Hospital admission to discharge (usually 4-7 days)

  2. Total Inpatient opioid consumption

    Total opioid consumption administered during the inpatient stay within the first 72 hours following initiation of the study medication. All opioid doses will be converted to oral morphine milligram equivalents (oMMEs) using standard conversion factors.

    Time frame: Start of study medication to 72 hours

Secondary outcomes

  1. Resource Length Of Stay (RLOS)

    Duration a patient spends in a healthcare facility as a measure of resource use

    Time frame: Hospital admission to discharge (usually 4-7 days)

  2. Case Mix Index

    The difference of Case Mix Index (CMI) between the placebo and experimental groups in days. The Case Mix Index is a hospital quality metric that reflects the average clinical complexity and resource intensity of the patient population. A higher CMI indicates a more resource-intensive patient group, while a lower CMI reflects a simpler, less costly case mix.

    Time frame: Hospital admission to discharge (usually 4-7 days)

  3. Total consumption of inpatient opioids

    Total consumption of inpatient opioids measured in oral morphine milligram equivalents (oMME)

    Time frame: Day of surgery to hospital discharge (usually 4-7 days)

  4. Pain Visual Analog Score

    Pain measured with an 11 point visual analog score (0 to 10) where 0 represents no pain and 10 represents the worst pain imaginable.

    Time frame: 0 (first pain score in Post Anesthesia Care Unit (PACU) or Intensive Care Unit(ICU)), 4, 8, 12, 24, 48, 72 hours after PACU/ICU admission and at hospital discharge

  5. Incidence of surgical outcomes

    Incidence of surgical outcomes such as bowel function, ileus, nausea, rapid response calls, surgical site infections, and Intensive Care Unit transfers

    Time frame: Surgery to 30 days after hospital discharge

  6. Incidence of treatment side effects

    Incidence of treatment side effects (double/blurry vision, tinnitus, sedation and events requiring early cessation of study treatment).

    Time frame: Anesthesia Induction to end of study treatment, less than or equal to 48 hours

  7. Incidence of meeting early discharge milestones

    Incidence of hospital discharge earlier than expected based on anticipated discharge day indicated at initial hospital booking

    Time frame: hospital discharge (usually 4-7 days after surgery)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Rouleau GW, Smith AW, Parrish CG, Allen LJ, Jayaram JE, Ruble SR, Adkins CM, Eden S, Shotwell MS, Yaghmour ET, Statzer NJ, Wanderer JP, Henson CP, Shams D, Kertai MD, Investigators I; IMPALA Investigators. Impact of PerioperAtive LidocAine Infusions on Enhanced Recovery After Noncardiac Surgery (IMPALA-ERAS) in an inpatient setting: rationale, design and protocol for a sequential, repeated crossover trial. BMJ Open. 2026 Sep 8;16(9):e120012. doi: 10.1136/bmjopen-2026-120012. PubMed 42711072 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.

Of 280 non-industry phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 24 months is above that.

Counting every sponsor, half of 295 studies reached it within 18 months; a quarter within 8 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2025
First posted
Nov 5, 2025
StartActual
Oct 26, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Oct 31, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
Vanderbilt University Medical Center is now Recruiting
Nov 2, 2026
Start date
Oct 31, 2026→Oct 26, 2026 (actual)
Nov 2, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAmerican Society of Anesthesiologists (ASA) class III-IV
Oct 15, 2026
Interventions
Added Drug: Dextrose 5% in water; removed Drug: Sodium Chloride 0.9%
Oct 15, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42711072 ↗
Oct 15, 2026
Show all 2 updates
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    Vanderbilt University Medical Center is now Recruiting
    Start date Oct 31, 2026→Oct 26, 2026 (now actual)
  2. Oct 15, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42711072 ↗
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAmerican Society of Anesthesiologists (ASA) class III-IV
    Interventions Added Drug: Dextrose 5% in water; removed Drug: Sodium Chloride 0.9%
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07224711
Responsible party
Danial Shams (Assistant Professor of Anesthesiology, Vanderbilt University Medical Center) — Principal investigator
First posted
Nov 5, 2025
Start date
Oct 26, 2026
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Danial Shams, MD
Contact
danial.shams@vumc.org
615-936-3198
Miklos Kertai, MD, MMHC, PhD
Contact
miklos.kertai@vumc.org
Danial Shams, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion